U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812481) titled 'Anticholinergic Burden and Osteoporosis in Rheumatoid Arthritis' on Feb. 02.
Brief Summary: Background: Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory rheumatological disease. Use of corticosteroids for more than 3 months in RA treatment is considered an important risk factor in terms of developing secondary osteoporosis and increasing the risk of fracture. The cumulative effect of taking one or more drugs with anticholinergic properties is called anticholinergic load. It is stated that anticholinergic load also increases the risk of fracture in individuals. The aim of this study is to investigate the effects of dr...